Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Global BET Inhibitors Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments - Research and Markets

Research and Markets
Posted on: 02 Aug 17

The "Global BET Inhibitors Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments" report has been added to Research and Markets' offering.

Pipeline Overview

Bromodomain and extra-terminal (BET) inhibitors are small molecule inhibitors including bromodomain 2 (BRD2), bromodomain 3 (BRD3), bromodomain 4 (BRD4) and bromodomain testis (BRDT), which have anti-proliferating properties.

These targets of inhibitors are supposed to bind with myc gene, which is a most desired target for cancer therapeutics. BET inhibitors are first-in-class targeted therapies that directly target bromodomain proteins to deliver a new therapeutic prospect as inhibition of epigenetic regulators.

BET inhibitor constitutes that class of drugs that prevents interactions between BET proteins, and transcription factors and acetylated histone.

This results in immunosuppressive and anti-cancer properties of BET inhibitor. BET inhibitors when administered, bind to acetylated lysine motifs, thus, preventing interaction between acetylated lysine and BET proteins.

This disrupts the gene expression and chromatin remodeling. Inhibition of certain growth promoting genes results in reducing tumor cell growth.

BET proteins play an important role in cell growth and development as transcriptional regulators. Inhibition of BET proteins offered a new therapeutic approach for the treatment of cancer, cardiovascular diseases and other diseases.

The discovery of BET proteins shows that they play a crucial role in transcriptional activation, and thus, have oncogenic potential. This has resulted in the development of several small molecule BET inhibitors.

Preclinical studies have shown promising results for many indications, both in in-vitro and in-vivo studies. There are many early phase clinical trials for these inhibitors that are presently testing the efficacy of BET inhibitors.

Key Topics Covered:

1. Research Background

2. Research Methodology

3. Executive Summary

4. Pipeline Outlook

5. Bet Inhibitors Pipeline Analysis By Phase (2017)

6 Competitive Landscape

7 Company Profiles

8 Appendix

For more information about this report visit https://www.researchandmarkets.com/research/j32krt/global_bet

View source version on businesswire.com: http://www.businesswire.com/news/home/20170802005666/en/

Business Wire
www.businesswire.com

Last updated on: 02/08/2017

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.